Key result
Obesity is linked to ~9 hours shorter ICU stay after robotic mitral valve surgery.
Why the study?
Although robotic cardiac surgery offers mitigated risks for obese patients requiring mitral valve surgery, the safety and outcomes of robotic mitral surgery in this population required evaluation.
Is robotic mitral valve surgery safe and effective in obese patients (BMI >= 30) compared to non-obese patients (BMI < 30)?
Cohort (n=123)
No
Is robotic mitral valve surgery safe and effective in obese patients (BMI >= 30) compared to non-obese patients (BMI < 30)?
Robotic mitral valve surgery can be safely performed in obese patients with postoperative outcomes comparable to non-obese patients, indicating obesity should not be a contraindication.
Answers are grounded in this paper and cite their sources.
Robotic mitral surgery may be safe in obese patients with similar outcomes; leaves open need for prospective confirmation before changing selection criteria.
INTRODUCTION: Robotic cardiac surgery offers mitigated risks for obese patients requiring mitral valve surgery. We aimed to study the safety of robotic mitral surgery in the obese patient population by analyzing the outcomes of mitral surgery patients in our center for robotic cardiac surgery. METHOD: This study retrospectively included 123 consecutive patients who underwent robotic mitral valve operations in a single center for robotic cardiac surgery. Patients with body mass index (BMI) ≥ 30 were compared against patients with BMI < 30 for demographic and operative parameters as well as postoperative outcomes. RESULTS: Mean BMI was 33.9 ± 2.8 in the obesity group (n = 87) and 25.4 ± 2.7 in the no-obesity group (n = 36). Female gender (80.6% vs. 52.9%, p = .004), diabetes (25.0% vs. 10.3%, p = .036), and hypertension (48.6% vs. 26.4%, p = .018) were more common in patients with obesity. The obesity group was operated with similar cardiopulmonary bypass and total operative times with the no-obesity group. Postoperative drainage and blood transfusion requirements were similar between the groups. Mechanical ventilation times (6.1 ± 2.2 vs. 8.0 ± 4.4 h, p = .003) and intensive care unit stay (20.4 ± 1.6 vs. 29.4 ± 3.7, p = .027) were shorter in the obesity group. Other postoperative outcomes of infection, atrial fibrillation, hospital stay duration, and readmission rates were similar between the groups. CONCLUSION: Robotic mitral surgery is safe to perform in obese patients. Obesity should not be a contraindication for robotic mitral surgery as obese patients have outcomes similar to nonobese patients despite increased challenges and risk-factors.
No takes yet. Share an insight, caveat, or question.
Şenay et al. (2021) conducted a cohort in Mitral valve disease requiring robotic mitral valve operations (n=123). Obesity (BMI >= 30) in patients undergoing robotic mitral valve operations vs. Non-obese patients (BMI < 30) undergoing robotic mitral valve operations was evaluated on Operative parameters and postoperative outcomes including mechanical ventilation time and ICU stay. Obese patients undergoing robotic mitral surgery had shorter ventilation and ICU stay and similar complication rates vs non-obese patients.
Synapse has enriched 10 related papers. Consider them for comparative context: